New Zealand Professional Investment Services Firm

Forsyth Barr

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

New Zealand Professional Investment Services Firm, Forsyth Barr

Equity Bottom-Up

<ul><li>The implementation of LCD, L35396 “Genetic Testing for Oncology” that would have resulted in Pacific Edge’s (PEB) CMS reimbursement ceasing on 17 July 2023 has been delayed</li><li>In the interim, PEB will continue to be reimbursed for its CMS tests (~77% of FY23 operating revenue) which is a clear near-term positive against prior expectations of a significant revenue reduction and business disruption (where the future reimbursement path was highly uncertain and potentially multiple years away).</li><li>Future decision timeframes are unknown and this decision does not mean the finalised LCD will be discontinued.</li></ul>

The implementation of LCD, L35396 “Genetic Testing for Oncology” that would have resulted in Pacific Edge’s (PEB) CMS reimbursement ceasing on 17 July 2023 has been delayedIn the interim, PEB will continue to be reimbursed for its CMS tests (~77% of FY23 operating revenue) which is a clear near-term positive against prior expectations of a significant revenue reduction and business disruption (where the future reimbursement path was highly uncertain and potentially multiple years away).Future decision timeframes are unknown and this decision does not mean the finalised LCD will be discontinued.

Pacific Edge (PEB): LCD Update – Signs of Life